Tarlatamab improves survival over chemo in 2L SCLC regardless of prior immunotherapy or chemo

Tarlatamab plus chemo-IO shows promising efficacy in extensive stage SCLC

ESMO 2025: Highlights and analysis

ESMO 2025: Latest in EGFR mutant NSCLC

Sacituzumab tirumotecan improves progression-free and overall survival in EGFR-TKI resistant NSCLC

Zongertinib shows high response rates in first-line HER2-mutant advanced NSCLC

Osimertinib plus chemo improves survival across high-risk subgroups in EGFR-mutated aNSCLC

Tarlatamab shows manageable safety profile with fewer toxicities than chemo in 2L SCLC

MCED blood test demonstrates high specificity, strong predictive value, and increased early cancer detection

Taletrectinib shows efficacy and tolerability in advanced ROS1+ NSCLC previously treated with entrectinib

NSCLC brain metastases: TTFields after SRS delays intracranial progression without affecting QoL

Supportive care intervention improves function and reduces fatigue in older lung cancer patients